[S-18-1] Preclinical biomarkers of Alzheimer's disease
Neurodegenerative diseases are characterized by a progressive decline of the motor and/or cognitive function caused by a selective loss of neurons within the central nervous system. Pathological changes at molecular and cellular levels precede the clinical onset by several years, underscoring a pressing need for initiation of interventions before the emergence of neurological symptoms. Using exquisite biomarkers, recent studies revealed the preclinical and prodromal progression of pathophysiology, as well as compensatory brain responses in several neurodegenerative diseases. This session aims to discuss the recent advancement of biomarker studies on presymptomatic subjects and the perspective on a preventive trial of disease-modifying therapies for devastating neurological disorders.
Chief of Laboratory for Cognitive Brain Sciences,
Department of Clinical and Experimental Neuroimaging,
National Center for Geriatrics and Gerontology, Obu, Japan
1985 Graduated from Faculty of Medicine, Kagoshima University, then studied clinical neurology
1995 Scientist, Department of Biofunctional Research, National Institute for Longevity Sciences
2001 Scientist, Max Planck Institute for Human Cognitive and Brain Sciences
2005- Current position
Abstract password authentication.
Password is written on a pocket program and name badge.